Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structre-activity studies

Journal of Medicinal Chemistry

Volumn 41, Issue 15, 1998, Pages 2806-2818

  Dragovich, Peter S ^a   Webber, Stephen E ^a   Babine, Robert E ^a   Fuhrman, Shella A ^a   Patick, Amy K ^a   Matthews, David A ^a   Lee, Caroline A ^a   Reich, Siegfried H ^a   Prins, Thomas J ^a   Marakovits, Joseph T ^a   Littlefield, Ethel S ^a   Zhou, Ru ^a   Tikhe, Jayashree ^a   Ford, Clifford E ^a   Wallace, Michael B ^a   Meador III, James W ^a   Ferre, Rose Ann ^a   Brown, Edward L ^a   Binford, Susan L ^a   Harr, James E V ^a   DeLisle, Dorothy M ^a   Worland, Stephen T ^a   more..

^a AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYSTEINE PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG CONFORMATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HELA CELL; HUMAN; HUMAN CELL; HUMAN RHINOVIRUS; NONHUMAN; PROTEINASE INHIBITION; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANIMALS; ANTIVIRAL AGENTS; BINDING SITES; CELL LINE, TRANSFORMED; CRYSTALLOGRAPHY, X-RAY; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DRUG DESIGN; DRUG STABILITY; HELA CELLS; HUMANS; OLIGOPEPTIDES; PROTEIN CONFORMATION; RATS; RATS, SPRAGUE-DAWLEY; RHINOVIRUS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL PROTEINS;

EID: 14444272282     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980068d     Document Type: Article

References (80)

1. (a) Couch, R. B. Rhinoviruses. In Virology, 2nd ed.; Fields, B. N., Knipe, D. M., Eds.; Raven Press: New York, 1990; Vol. 1, Chapter 22, pp 607-629.
2. (b) McKinlay, M. A.; Pevear, D. C.; Rossmann, M. G. Treatment of the Picornavirus Common Cold by Inhibitors of Viral Uncoating and Attachment. Annu. Rev. Microbiol. 1992, 46, 635-654.
3. (c) Phillpotts, R. J.; Tyrrell, D. A. J. Rhinovirus Colds. Br. Med. Bull. 1985, 41, 386-390.
4. (d) Gwaltney, J. M. The Common Cold. In Principles and Practices of Infectious Diseases; Mandell, G. L., Douglas, R. G., Bennett, J. E., Eds.; John Wiley & Sons: New York, 1985; Chapter 38, pp 351-355.
5. (e) Gwaltney, J. M. Rhinoviruses. In Viral Infections of Humans; Evans, A. S., Ed.; Plenum Publishing Corp.: New York, 1982; Chapter 20, pp 491-517.
6. (a) Rueckert, R. R. Picornaviridae and Their Replication. In Virology, 2nd ed.; Fields, B. N., Knipe, D. M., Eds.; Raven Press: New York, 1990; Vol. 1, Chapter 20, pp 507-548.
7. (b) Kräusslich, H.-G.; Wimmer, E. Viral Proteinases. Annu. Rev. Biochem. 1988, 57, 701-754.
8. (a) Orr, D. C.; Long, A. C.; Kay, J.; Dunn, B. M.; Cameron, J. M. Hydrolysis of a Series of Synthetic Peptide Substrates by the Human Rhinovirus 14 3C Proteinase, Cloned and Expressed in Escherichia coli. J. Gen. Virol. 1989, 70, 2931-2942.
9. (b) Cordingley, M. G.; Register, R. B.; Callahan, P. L.; Garsky, V. M.; Colonno, R. J. Cleavage of Small Peptides In Vitro by Human Rhinovirus 14 3C Protease Expressed in Escherichia coli. J. Virol. 1989, 63, 5037-5045.
10. (a) Matthews, D. A.; Smith, W. W.; Ferre, R. A.; Condon, B.; Budahazi, G.; Sisson, W.; Villafranca, J. E.; Janson, C. A.; McElroy, H. E.; Gribskov, C. L.; Worland, S. Structure of Human Rhinovirus 3C Protease Reveals a Trypsin-like Polypeptide Fold, RNA-Binding Site, and Means for Cleaving Precursor Polyprotein. Cell 1994, 77, 761-771.
11. (b) Allaire, M.; Chernaia, M. M.; Malcolm, B. A.; James, M. N. G. Picornaviral 3C Cysteine Proteinases Have a Fold Similar to Chymotrypsin-like Serine Proteinases. Nature 1994, 369, 72-76.
12. (c) Bazan, J. F.; Fletterick, R. J. Viral Cysteine Proteases are Homologous to the Trypsin-like Family of Serine Proteases: Structural and Functional Implications. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 7872-7876.
13. (d) Gorbalenya, A. E.; Blinov, V. M.; Donchenko, A. P. Poliovirus-encoded Proteinase 3C: A Possible Evolutionary Link Between Cellular Serine and Cysteine Proteinase Families. FEBS Lett. 1986, 194, 253-257.
14. (a) Lee, W.-M.; Wang, W.; Rueckert, R. R. Complete Sequence of the RNA Genome of Human Rhinovirus 16, a Clinically Useful Common Cold Virus Belonging to the ICAM-1 Receptor Group. Virus Genes 1994, 9, 177-181.
15. (b) Aschauer, B.; Werner, G.; McCray, J.; Rosenwirth, B.; Bachmayer, H. Biologically, Active Protease 3C of Human Rhinovirus 1A is Expressed from a Cloned cDNA Segmant in Escherichia coli. Virology 1991, 184, 587-594.
16. (c) Hughes, P. J.; North, C.; Jellis, C. H.; Minor, P. D.; Stanway, G. The Nucleotide Sequence of Human Rhinovirus 1B: Molecular Relationships within the Rhinovirus Genus. J. Gen. Virol. 1988, 69, 49-58.
17. (d) Duechler, M.; Skern, T.; Sommergruber, W.; Neubauer, C.; Gruendler, P.; Fogy, I.; Blaas, D.; Kuechler, E. Evolutionary Relationships Within the Human Rhinovirus Genus: Comparison of Serotypes 89, 2, and 14. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 2605-2609.
18. (e) Werner, G.; Rosenwirth, B.; Bauer, E.; Siefert, J.-M.; Werner, F.-J.; Besemer, J. Molecular Cloning and Sequence Determination of the Genomic Regions Encoding Protease and Genome-Linked Protein of Three Picornaviruses. J. Virol. 1986, 57, 1084-1093.
19. (f) Skern, T.; Sommergruber, W.; Blaas, D.; Gruendler, P.; Fraundorfer, F.; Pieler, C.; Fogy, I.; Kuechler, E. Human Rhinovirus 2: Complete Nucleotide Sequence and Proteolytic Processing Signals in the Capsid Protein Region. Nucleic Acids Res. 1985, 13, 2111-2126.
20. (g) Callahan, P. L.; Mizutani, S.; Colonno, R. J. Molecular Cloning and Complete Sequence Determination of RNA Genome of Human Rhinovirus Type 14. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 732-736.
21. (h) Stanway, G.; Hughes, P. J.; Mountford, R. C.; Minor, P. D.; Almond, J. W. The Complete Nucleotide Sequence of a Common Cold Virus: Human Rhinovirus 14. Nucleic Acids Res. 1984, 12, 7859-7875.
22. Hamparian, V. V.; Colonno, R. J.; Cooney, M. K.; Dick, E. C.; Gwaltney, J. M., Jr.; Hughes, J. H.; Jordan, W. S., Jr.; Kapikian, A. Z.; Mogabgab, W. J.; Monto, A.; Phillips, C. A.; Rueckert, R. R.; Schieble, J. H.; Stott, E. J.; Tyrrell, D. A. J. A Collaborative Report: Rhinoviruses-Extension of the Numbering System From 89 to 100. Virology 1987, 159, 191-192.
23. Carrasco, L. Picornavirus Inhibitors. Pharmacol. Ther. 1994, 64, 215-290.
24. (a) Oren, D. A.; Zhang, A.; Nesvadba, H.; Rosenwirth, B.; Arnold, E. Synthesis and Activity of Piperazine-containing Antirhinoviral Agents and Crystal Structure of SDZ 880-061 Bound to Human Rhinovirus 14. J. Mol. Biol. 1996, 259, 120-134 and references therein.
25. (b) Diana, G. D.; Rudewicz, P.; Pevear, D. C.; Nitz, T. J.; Aldous, S. C.; Aldous, D. J.; Robinson, D. T.; Draper, T.; Dutko, F. J.; Aldi, C.; Gendron, G.; Oglesby, R. C.; Volkots, D. L.; Reuman, M.; Bailey, T. R.; Czerniak, R.; Block, T.; Roland, R.; Oppermann, J. Picornavirus Inhibitors: Trifluoromethyl Substitution Provides a Global Protective Effect Against Hepatic Metabolism. J. Med. Chem. 1995, 38, 1355-1371 and references therein.
26. Tebbe, M. J.; Spitzer, W. A.; Victor, F.; Miller, S. C.; Lee, C. C.; Sattelberg, T. R., Sr.; McKinney, E.; Tang, J. C. Antirhino/ Enteroviral Vinylacetlyene Benzimidazoles: A Study of Their Activity and Oral Plasma Levels in Mice. J. Med. Chem. 1997, 40, 3937-3946 and references therein.
27. 1 Glutamine Isosteric Replacements. J. Med. Chem. 1998, 41, 2786-2805.
28. (b) Jungheim, L. N.; Cohen, J. D.; Johnson, R. B.; Villarreal, E. C.; Wakulchik; M.; Loncharich, R. J.; Wang, Q. M. Inhibition of Human Rhinovirus 3C Protease by Homophthalimides. Bioorg. Med. Chem. Lett. 1997, 7, 1589-1594.
29. (c) Webber, S. E.; Tikhe J.; Worland, S. T.; Fuhrman, S. A.; Hendrickson, T. F.; Matthews, D. A.; Love, R. A.; Patick, A. K; Meador, J. W.; Ferre, R. A.; Brown, E. L.; DeLisle, D. M.; Ford, C. E.; Binford, S. L. Design, Synthesis, and Evaluation of Nonpeptidic Inhibitors of Human Rhinovirus 3C Protease. J. Med. Chem. 1996, 39, 5072-5082.
30. (d) Shepherd, T. A.; Cox, G. A.; McKinney, E.; Tang, J.; Wakulchik, M.; Zimmerman, R. E.; Villarreal, E. C. Small Peptidic Aldehyde Inhibitors of Human Rhinovirus 3C Protease. Bioorg. Med. Chem. Lett. 1996, 6, 2893-2896.
31. (e) Brill, G. M.; Kati, W. M.; Montgomery, D.; Karwowski, J. P.; Humphrey, P. E.; Jackson, M.; Clement, J. J.; Kadam, S.; Chen, R. H.; McAlpine, J. B. Novel Triterpene Sulfates from Fusarium compactum Using a Rhinovirus 3C Protease Inhibitor Screen. J. Antibiot. 1996, 49, 541-546.
32. (f) Sham, H. L.; Rosenbrook, W.; Kati, W.; Betebenner, D. A.; Wideburg, N. E.; Saldivar, A.; Plattner, J. J.; Norbeck, D. W. Potent Inhibitor of the Human Rhinovirus (HRV) 3C Protease Containing a Backbone Modified Glutamine. J. Chem. Soc., Perkin Trans, 1 1995, 1081-1082.
33. (g) Malcolm, B. A.; Lowe, C.; Shechosky, S.; McKay, R. T.; Yang, C. C.; Shah, V. J.; Simon, R. J.; Vederas, J. C.; Santi, D. V. Peptide Aldehyde Inhibitors of Hepatitis A Virus 3C Proteinase. Biochemistry 1995, 34, 8172-8179.
34. (h) Kaldor, S. W.; Hammond, M.; Dressman, B. A.; Labus, J. M.; Chadwell, F. W.; Kline, A. D.; Heinz, B. A. Glutamine-Derived Aldehydes for the Inhibition of Human Rhinovirus 3C Protease. Bioorg. Med. Chem. Lett. 1995, 5, 2021-2026.
35. (i) Kadam, S.; Poddig, J.; Humphrey, P.; Karwowski, J.; Jackson, M.; Tennent, S.; Fung, L.; Hochlowski, J.; Rasmussen, R.; McAlpine, J. Citrinin Hydrate and Radicinin: Human Rhinovirus 3C-Protease Inhibitors Discovered in a Target-Directed Microbial Screen. J. Antibiot. 1994, 47, 836-839.
36. (j) Singh, S. B.; Cordingley, M. G.; Ball, R. G.; Smith, J. L.; Dombrowski, A. W.; Goetz, M. A. Structure and Stereochemistry of Thysanone: A Novel Human Rhinovirus 3C-Protease Inhibitor from Thysanophora penicilloides. Tetrahedron Lett. 1991, 32, 5279-5282.
37. (k) Skiles, J. W.; McNeil, D. Spiro Indolinone Beta-Lactams, Inhibitors of Poliovirus and Rhinovirus 3C-Proteinases. Tetrahedron Lett. 1990, 31, 7277-7280.
38. Cordingley, M. G.; Callahan, P. L.; Sardana, V. V.; Garsky, V. M.; Colonno, R. J. Substrate Requirements of Human Rhinovirus 3C Protease for Peptide Cleavage in Vitro. J. Biol. Chem. 1990, 265, 9062-9065.
39. 2′ etc.) is described in the following: Schechter, I.; Berger, A. On the Size of the Active Site in Proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27, 157-162.
40. (a) McGrath, M. E.; Klaus, J. L.; Barnes, M. G.; Brömme, D. Crystal Structure of Human Cathepsin K Complexed With a Potent Inhibitor. Nature Struct. Biol. 1997, 4, 105-109.
41. (b) Brömme, D.; Klaus, J. L.; Okamoto, K.; Rasnick, D.; Palmer, J. T. Peptidyl Vinyl Sulphones: A New Class of Potent and Selective Cysteine Protease Inhibitors. Biochem. J. 1996, 315, 85-89.
42. (c) Palmer, J. T.; Rasnick, D.; Klaus, J. L.; Brömme, D. Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors. J. Med. Chem. 1995, 38, 3193-3196.
43. (d) Liu, S.; Hanzlik, R. P. Structure - Activity Relationships for Inhibition of Papain by Peptide Michael Acceptors. J. Med. Chem. 1992, 35, 1067-1075.
44. (e) Hanzlik, R. P.; Thompson, S. A. Vinylogous Amino Acid Esters: A New Class of Inactivators for Thiol Proteases. J. Med. Chem. 1984, 27, 711-712.
45. In the discussion of structure - activity relationships, the notation "3CP" indicates 3C protease derived from HRV-14 unless otherwise specified.
46. The observed antiviral activity was indicated to result primarily from 3CP inhibition by strong correlation with disruption of in vitro proteolytic processing: Patick A. K., et al. manuscript in preparation.
47. 50 value. However, the most active antiviral agents were clearly soluble and nontoxic to more than 10 times the reported ECso values. See the Experimental Section for additional details.
48. (a) Babine, R. E.; Bender, S. L. Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design. Chem. Rev. 1997, 97, 1359-1472.
49. (b) Bohacek, R. S.; McMartin, C.; Guida, W. C. The Art and Practice of Structure-Based Drug Design: A Molecular Modeling Perspective. Med. Res. Rev. 1996, 16, 3-50.
50. (c) Greer, J. Erickson, J. W.; Baldwin, J. J.; Varney, M. D. Application of the Three-Dimensional Structures of Protein Target Molecules in Structure-Based Drug Design. J. Med. Chem. 1994, 37, 1035-1054.
51. In the discussion of the X-ray crystal structure, the notation "3CP" indicates 3C protease derived from HRV-2. This protein provided diffraction quality crystals more routinely than the serotype 14-derived protease. The inhibitor-binding regions of the two enzymes do not differ significantly: Matthews, D. A.; et al. manuscript in preparation.
52. (a) Martin, P. D.; Malkowski, M. G.; DiMaio, J.; Konishi, Y.; Ni, F.; Edwards, B. F. P. Bovine Thrombin Complexed with an Uncleavable Analogue of Residues 7-19 of Fibrinogen Aα: Geometry of the Catalytic Triad and Interactions of the P1′, P2′, and P3′ Substrate Residues. Biochemistry 1996, 35, 13030-13039.
53. (b) Kurinov, I. V.; Harrison, R. W. Two Crystal Structures of the Leupeptin-Trypsin Complex. Protein Sci. 1996, 5, 752-758.
54. (c) Blanchard, H.; James, M. N. G. A Crystallographic Reinvestigation into the Structure of Streptomyces griseus Proteinase A Reveals an Acyl-enzyme Intermediate. J. Mol. Biol. 1994, 241, 574-587.
55. (d) Nienaber, V. L.; Breddam, K; Birktoft, J. J. A Glutamic Acid Specific Serine Protease Utilizes a Novel Histidine Triad in Substrate Binding. Biochemistry 1993, 32, 11469-11475.
56. (e) Edwards, P. D.; Meyer, E. F., Jr.; Vijayalakshmi, J.; Tuthill, P. A.; Andisik, D. A.; Gomes, B.; Strimpler, A. Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl α-Ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex Between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole. J. Am. Chem. Soc. 1992, 114, 1854-1863.
57. For the examination of various amino acid residues at this location within the peptide-derived 3CP inhibitors, see the subsequent paper in this issue. (Dragovich, P. S.; Webber, S. E.; Babine, R. E.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Reich, S. H.; Marakovits, J. T.; Prins, T. J.; Zhou, R.; Tikhe, J.; Littlefield, E. S.; Bleckman, T. M.; Wallace, M. B.; Little, T. L.; Ford, C. E.; Meador, J. W., III; Ferre, R. A.; Brown, E. L.; Binford, S. L.; DeLisle, O. M.; Worland, S. T. Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 2. Peptide Structure - Activity Studies. J. Med. Chem. 1998, 41, 2819-2834.)
58. For the optimization of this portion of the peptide-derived 3CP inhibitors, see the subsequent paper in this issue. (Dragovich, P. S.; Webber, S. E.; Babine, R. E.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Reich, S. H.; Marakovits, J. T.; Prins, T. J.; Zhou, R.; Tikhe, J.; Littlefield, E. S.; Bleckman, T. M.; Wallace, M. B.; Little, T. L.; Ford, C. E.; Meador, J. W., III; Ferre, R. A.; Brown, E. L.; Binford, S. L.; DeLisle, O. M.; Worland, S. T. Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 2. Peptide Structure - Activity Studies. J. Med. Chem. 1998, 41, 2819-2834.)
59. Nahm, S.; Weinreb, S. M. N-Methoxy-N-methylamides as Effective Acylating Agents. Tetrahedron Lett. 1981, 22, 3815-3818.
60. Smith, R. A.; Copp, L. J.; Donnelly, S. L.; Spencer, R. W.; Krantz, A. Inhibition of Cathepsin B by Peptidyl Aldehydes and Ketones: Slow-Binding Behavior of a Trifluoromethyl Ketone. Biochemistry 1988, 27, 6568-6573.
61. The "Z" olefin required for the synthesis of compound 2 was prepared by the method described in the following: Still, W. C.; Gennari, C. Direct Synthesis of Z-Unsaturated Esters. A Useful Modification of the Horner-Emmons Olefination. Tetrahedron Lett. 1983, 24, 4405-4408.
62. 4 in i-PrOH.
63. 3SiH during the preparation of 60 resulted in poor formation of the desired compound.
64. Carboxylic acid 10 was prepared by olefination of 70 with (tert-butoxycarbonylmethylene)triphenylphosphorane followed by TFA deprotection. The attempted basic hydrolysis of 3 and related esters resulted in decomposition.
65. The lack of extensive racemization during ester hydrolysis was inferred from the subsequent absence of significant diastereomers of the Cbz-L-Leu-L-Phe-OH coupling product.
66. Still, W. C.; Kahn, M.; Mitra, A. Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution. J. Org. Chem. 1978, 43, 2923-2925.
67. King, H. isoOxazolidine and Tetrahydro-1:2-isooxazine. J. Chem. Soc. 1942, 432-433.
68. Gribble, G. W.; Hoffman, J. H. Reactions of Sodium Borohydride in Acidic Media; VI. Reduction of Indoles with Cyanoborohydride in Acetic Acid. Synthesis 1977, 859-860.
69. Iwao, M.; Kuraishi, T. Directed Lithiation of 1-(tert-Butoxycarbonyl)indolines. A Convenient Route to 7-Substituted Indolines. Heterocycles 1992, 34, 1031-1038.
70. Borror, A. L.; Chinoporos, E.; Filosa, M. P.; Herchen, S. R.; Petersen, C. P.; Stern, C. A.; Onan, K. D. Regioselectivity of Electrophilic Aromatic Substitution: Syntheses of 6- and 7-Sulfamoylindolines and -indoles. J. Org. Chem. 1988, 53, 2047-2052.
71. Freudenreich, C.; Samama, J.-P.; Biellmann, J.-F. Design of Inhibitors from the Three-Dimensional Structure of Alcohol Dehydrogenase. Chemical Synthesis and Enzymatic Properties. J. Am. Chem. Soc. 1984, 106, 3344-3353.
72. Baldwin, J. E.; Peavy, R. E. Diarylmethylene-Tetracyanoethylene Cycloadditions. J. Org. Chem. 1971, 36, 1441-1443.
73. Ikuta, H.; Shirota, H.; Kobayashi, S.; Yamagishi, Y.; Yamada, K.; Yamatsu, I.; Katayama, K. Synthesis and Antiinflammatory Activities of 3-(3,5-Di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones. J. Med. Chem. 1987, 30, 1995-1998.
74. (a) Flitsch W.; Lubisch, W. On the Reaction of 2-Pyrrolecarbaldehyde with Hetero-substituted Ethenes. Chem. Ber. 1984,117, 1424-1435.
75. (b) Eberlein, W.; Heider, J.; Machleidt, H. Steroidal Cardiotonics, II. Replacement of the Butenolide Ring of Cardiac Glycosides by Unbranched Open Chain √-Electron Systems. Chem. Ber. 1974, 107, 1275-1284.
76. Leatherbarrow, R. J. ENZFITTER, Biosoft, Ferguson, MO 63135.
77. Weislow, O. S.; Kiser, R.; Fine, D. L.; Bader, J.; Shoemaker. R. H.; Boyd, M. R. New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Synthetic and Natural Products for Aids-Antiviral Activity. J. Natl. Cancer Inst. 1989, 81, 577-586.
78. Andries, K.; Dewindt, B.; Snoeks, J.; Willebrords, R.; Van Eemeren, K.; Stokbroekx, R.; Janssen, P. A. J. In Vitro Activity of Pirodavir (R 77975), a Substituted Phenoxy-Pyridazinamine with Broad-Spectrum Antipicornaviral Activity. Antimicrob. Agents Chemother. 1992, 36, 100-107.
79. X-PLOR, version 3.1. Brünger A. T. X-PLOR v3.1 Manual; Yale University Press: New Haven, CT, 1992.
80. Matthews, D. A., unpublished results.